Evaluation of biomarkers for cardiotoxicity of anthracyclin-based chemotherapy
| Autor: | Susanne Osanto, H. J. Ritsema van Eck, Freerk Broeyer, B. E. P. B. Ballieux, J. Burggraaf, Rik C. Schoemaker, A. Q. M. J. van Steijn, Adam F. Cohen |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2008 |
| Předmět: |
Oncology
Male Cancer Research medicine.medical_specialty Cardiotoxicity Pathology Chemotherapy Original Paper Electrodiagnosis medicine.diagnostic_test business.industry medicine.medical_treatment General Medicine Middle Aged Electrocardiography Cardiovascular Diseases Internal medicine Medicine Humans Anthracyclines Female business Biomarkers |
| Zdroj: | Journal of Cancer Research and Clinical Oncology |
| ISSN: | 1432-1335 0171-5216 |
| Popis: | Introduction The clinical assessment of the myocardial damage caused by anthracyclin (ANT)-therapy is difficult. Therefore a study was performed to evaluate non-invasive markers of anthracyclin-induced cardiac effects, with emphasis on course-to-course variation. Methods Eligible for study participation were patients, without known cardiologic abnormalities who did not use cardiotoxic medication (except for ANT-therapy), who had previously completed at least three cycles of anthracyclin-containing chemotherapy (n = 14) and patients who were ANT-naïve and who were scheduled to receive doxorubicin-containing chemotherapy (n = 12). Seven patients in this last group also completed at least three cycles and were available for follow-up assessments; thus a total population of 21 patients (12F/9M) completed at least three courses ANT-chemotherapy. In these patients blood samples and ECG-recordings were taken within 6 months after completion of ANT-therapy. In 12 patients (10F/2M) assessments were also done before, immediately afterwards and at 24 h after each course of ANT. Results and Conclusions In the patients who completed chemotherapy, NT-proBNP was 277% (n = 21; 95% CI: 86–661%, P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink